IL144355A0 - 5-ht1f agonists - Google Patents

5-ht1f agonists

Info

Publication number
IL144355A0
IL144355A0 IL14435500A IL14435500A IL144355A0 IL 144355 A0 IL144355 A0 IL 144355A0 IL 14435500 A IL14435500 A IL 14435500A IL 14435500 A IL14435500 A IL 14435500A IL 144355 A0 IL144355 A0 IL 144355A0
Authority
IL
Israel
Prior art keywords
ht1f agonists
ht1f
agonists
Prior art date
Application number
IL14435500A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL144355A0 publication Critical patent/IL144355A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14435500A 1999-02-26 2000-02-11 5-ht1f agonists IL144355A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26
PCT/US2000/002505 WO2000050426A2 (en) 1999-02-26 2000-02-11 Furo[3, 2-b]pyridines as 5-ht1f agonists

Publications (1)

Publication Number Publication Date
IL144355A0 true IL144355A0 (en) 2002-05-23

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14435500A IL144355A0 (en) 1999-02-26 2000-02-11 5-ht1f agonists

Country Status (21)

Country Link
EP (1) EP1155020B1 (tr)
JP (1) JP2002537398A (tr)
KR (1) KR20010102355A (tr)
AR (1) AR026856A1 (tr)
AT (1) ATE258935T1 (tr)
AU (1) AU3354000A (tr)
BR (1) BR0008479A (tr)
CA (1) CA2371784A1 (tr)
CO (1) CO5150234A1 (tr)
DE (1) DE60008073T2 (tr)
EA (1) EA200100918A1 (tr)
ES (1) ES2214256T3 (tr)
HU (1) HUP0200245A2 (tr)
ID (1) ID30056A (tr)
IL (1) IL144355A0 (tr)
NO (1) NO20014127L (tr)
PE (1) PE20001432A1 (tr)
PL (1) PL350864A1 (tr)
TR (1) TR200102436T2 (tr)
WO (1) WO2000050426A2 (tr)
ZA (1) ZA200106109B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー ５−ｈｔ１ｆアゴニストとしての置換（４−アミノシクロヘキセン−１−イル）フェニルおよび（４−アミノシクロヘキセン−１−イル）ピリジニル化合物
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
NO20014127D0 (no) 2001-08-24
WO2000050426A2 (en) 2000-08-31
EP1155020A2 (en) 2001-11-21
PE20001432A1 (es) 2000-12-18
AR026856A1 (es) 2003-03-05
KR20010102355A (ko) 2001-11-15
BR0008479A (pt) 2002-01-29
WO2000050426A3 (en) 2000-12-21
ID30056A (id) 2001-11-01
HUP0200245A2 (en) 2002-06-29
CO5150234A1 (es) 2002-04-29
TR200102436T2 (tr) 2002-06-21
EP1155020B1 (en) 2004-02-04
NO20014127L (no) 2001-08-24
DE60008073D1 (de) 2004-03-11
ZA200106109B (en) 2002-07-25
CA2371784A1 (en) 2000-08-31
ES2214256T3 (es) 2004-09-16
ATE258935T1 (de) 2004-02-15
DE60008073T2 (de) 2004-08-05
JP2002537398A (ja) 2002-11-05
AU3354000A (en) 2000-09-14
PL350864A1 (en) 2003-02-10
EA200100918A1 (ru) 2002-02-28

Similar Documents

Publication Publication Date Title
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE50008011D1 (en) Thixotropierungsmittel
DE50002614D1 (en) Sigma-delta-modulator
DE60007505D1 (en) Propargyletherderivate
DE60011809D1 (en) Oxcarbazepinsuspension
DE50000137D1 (en) Spirofluorenopyrane
DE59909975D1 (en) Testleck
AU4961499A (en) 5-HT1f agonists
DE10081629D2 (en) Seilzugbefestigung
DE60001313D1 (en) Imidazodiazepinderivate
HK1047241A1 (zh) 放射線防護劑
DE60044882D1 (en) Ie
DE50009469D1 (en) Common-rail-injektor
GB0015517D0 (en) Somatostatin agonists
HUP0004317A3 (en) 5-ht1f agonists
PL352763A1 (en) Somatostatin agonists
IL144355A0 (en) 5-ht1f agonists
DE50010757D1 (en) Stilbenaufheller
PL353372A1 (en) Substituted heterocyclyl-2h-chromenes
DE50008218D1 (en) Common-rail-injektor
DE50012999D1 (en) Stirnwandisolation
DE60004080D1 (en) Centroidintegration
GB9914798D0 (en) Ensure